Effects of the combination of dexamethasone and fibroblast growth factor‑2 on differentiation of osteoprecursor cells

Introduction

Dexamethasone is a potent synthetic member of the glucocorticoid class of steroid hormones (1). Dexamethasone is reported to have major effects on a number of organ systems, including the cardiovascular, endocrine, gastrointestinal, ophthalmic and musculoskeletal systems (2). Dexamethasone is a potent modulator of osteogenic differentiation and previous studies have shown that dexamethasone increased the bone formation capacity of osteoprogenitor cells in vitro (3,4). Furthermore, it was reported that dexamethasone acts synergistically with growth factors (5). Fibroblast growth factor-2 (FGF-2) is reported to have numerous biological activities, including stimulation of cell growth, migration, angiogenesis, wound healing, tissue repair, differentiation and morphogenesis (5). In addition, FGF-2 is known to play a critical role in bone growth and development (6–8).

A previous report showed that dexamethasone and FGF-2 are required to maintain cell propagation, alkaline phosphatase (ALP) expression and osteocalcin secretion and act synergistically. However, protein content is FGF-2-dependent and mineralization is dexamethasone-dependent (9). Controversial opinions exist with regard to the combined effects of dexamethasone and FGF-2 in proliferation, differentiation and mineralization. FGF-2, in combination with dexamethasone, were previously found to stimulate the proliferation and osteoblastic differentiation of human adipose tissue-derived mesenchymal stromal cells (10). In another study, dexamethasone increased mineralization, while FGF-2 blocked this activity and the addition of dexamethasone to FGF-2 did not alter FGF-2-associated inhibition (5).

The current study aimed to examine the dose-dependent impact of dexamethasone and FGF-2 on the differentiation of osteoprecursor cells. The ALP test was performed to assess differentiation and protein expression associated with bone formation, including bone morphogenetic protein receptor-IA (BMPRIA) and bone morphogenetic protein receptor-II (BMPRII) and phosphor-Smad1/5/8 (pSmad1/5/8) was evaluated by western blot analysis.

Materials and methods

Cell culture

Murine calvarial osteoprecursor cells (MC3T3-E1) were plated and cultures were maintained in α-minimum essential medium (αMEM) supplemented with 10% fetal bovine serum, antibiotics [penicillin 100 U/ml and streptomycin 100 μg/ml (all Invitrogen Life Technologies, Carlsbad, CA, USA)], 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate (both Sigma-Aldrich, St. Louis, MO, USA). Cells were stimulated with dexamethasone and FGF-2 at a final concentration of 10 nM (D1) to 100 nM (D2) for dexamethasone and 2 ng/ml (F1) to 20 ng/ml (F2) for FGF-2. The cultures were maintained in a humidified atmosphere with 5% CO2 and 95% air at 37°C.

Protein measurement

Cells were incubated in αMEM in the presence of ascorbic acid and β-glycerophosphate for two days. Protein content was determined based on the Bradford method, using the Coomassie protein assay reagent in comparison with a series of bovine serum albumin as internal standards (11). The absorbance was recorded at 595 nm using the microplate spectrophotometer system (BioTek, Winooski, VT, USA) and results are presented as the percentage of control values.

ALP activity assays

The ALP assay for osteoblast differentiation was performed after incubation. MC3T3-E1 murine calvarial preosteoblasts were lysed with a buffer containing 10 mM Tris-HCl (pH 7.4) and 0.2% Triton X-100 and were then sonicated for 20 sec at 4°C. Samples were incubated with 10 mM p-nitrophenylphosphate as a substrate in 100 mM glycine buffer (pH 10.5) containing 1 mM MgCl2 at 37°C in a water bath. The absorbance at 405 nm was measured using a microplate reader (BioTek) and ALP activities were normalized with respect to total protein content (12,13).

Western blot analysis

Osteoprecusor cells were washed twice with ice-cold phosphate-buffered saline and solubilized with a lysis buffer. The lysates were centrifuged at 16,000 × g for 20 min at 4°C to remove the nuclear pellet. The supernatants were boiled in a sodium dodecyl sulfate sample buffer containing β-mercaptoethanol. Equal amounts extracts were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto polyvinylidene fluoride microporous membranes (Immobilon-P membranes; Millipore Corporation, Billerica, MA, USA). The membranes were blocked for >1 h in 0.1% (v/v) phosphate-buffered saline and Tween-20 containing 5% (w/v) powdered milk. Each membrane was probed with the desired antibodies diluted in the same buffer at the recommended concentrations. Each membrane was incubated with horseradish peroxidase-conjugated secondary antibody and then the washed blot was developed using enhanced chemiluminescence detection kits (14,15). Mouse antibodies against BMPRIA, BMPRII and pSmad1/5/8 and horseradish peroxidase secondary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and Cell Signaling Technology, Inc. (Danvers, MA, USA).

Statistical analysis

Results are expressed as means ± standard deviations of the experiments. Two-way analysis of variance (ANOVA) with post-hoc tests were performed to determine the combination effects of dexamethasone and FGF-2 using a commercially available program (SPSS 12 for Windows; SPSS Inc., Chicago, IL, USA). A one-way ANOVA was used to compare data within the same groups. P<0.05 was considered to indicate a statistically significant difference.

Results

Protein measurement

The protein content in each culture plate was determined (Fig. 1). The results showed that the protein content of the cultures grown with the osteogenic differentiation media in the presence of FGF-2 at 2 ng/ml (F1) was increased compared with that of the control. However, the addition of dexamethasone to the cultures uniformly showed a decrease of protein content when compared with the dexamethasone-unloaded group.

Figure 1 Determination of protein measurement in each group.

ALP activity assay

ALP activity was increased when cells were treated with dexamethasone, with the highest value at 100 nM (Fig. 2). Cultures grown in the presence of 20 ng/ml FGF-2 exhibited an increased value of ALP activity when compared with 10 and 100 nM dexamethasone. Similarly, cultures grown in the presence of 20 ng/ml FGF-2 and 10 nM dexamethasone exhibited an increased value of ALP activity when compared with the 10 nM dexamethasone-only group. The addition of 20 ng/ml FGF-2 to 100 nM dexamethasone resulted in an increase of ALP activity in comparison with that of the 100 nM dexamethasone group. However, statistically significant differences were not observed (P>0.05).

Figure 2 Relative value of ALP activity. *A statistically significant increase was observed when compared with the control (unloaded group) (P<0.05 vs. control).

Western blot analysis

A western blot analysis was performed to detect the protein expression following treatment with dexamethasone and FGF-2 (Fig. 3A). The results showed that the addition of 20 ng/ml FGF-2 and 100 nM dexamethasone appeared to increase the expression of BMPRIA and BMPRII (Fig. 3B and C). Similarly, the combination of 20 ng/ml FGF-2 and 100 nM dexamethasone produced the highest pSmad1/5/8 expression, yielding 260%, while the untreated control was considered to be 100% (Fig. 3D).

Figure 3 (A) Western blot analysis to detect the protein expression of bone morphogenetic protein receptor-IA, bone morphogenetic protein receptor-II and phosphor-Smad1/5/8. (B) Quantitative analysis of the protein expression of bone morphogenetic protein receptor-IA by densitometry. (C) The relative expression of bone morphogenetic protein receptor-II. (D) The relative value for the protein expression of phosphor-Smad1/5/8.

Discussion

In the current study, the combined effects of dexamethasone and FGF-2 on protein content, differentiation and protein expression of osteoblast progenitor cells under predetermined concentrations (10 and 100 nM dexamethasone; 2 and 20 ng/ml FGF-2) were studied. The study examined the mechanisms of dexamethasone and FGF-2 on the regulation of the protein expression in mouse preosteoblastic cells. In addition, evaluations were conducted to identify whether combinations of dexamethasone and FGF-2 produced effects additively, synergistically or competitively.

An increase in protein content was achieved with the 2 ng/ml FGF-2 group under osteogenic differentiation media. This is in agreement with a previous report demonstrating that FGF-2 affected the proliferation and differentiation of the tested cells (14).

The treatment of dexamethasone on the preosteoblast clearly showed an increased level of ALP activity. This is similar to previous reports which showed that treatment with 10−8 to 10−7 M dexamethasone presented a significant induction in the ALP activity of human bone marrow cells, leading to the osteoblast differentiation of bone marrow cells (4,16). The current study showed that the addition of 20 ng/ml FGF-2 to 100 nM dexamethasone produced an increase in ALP activity in comparison with that of the 100 nM dexamethasone group, however, this was not observed to be statistically significant.

Since BMP pathways are involved in osteoblast differentiation, factors associated with BMP signaling were evaluated (17). The present study clearly showed that the expression of BMPRIA and BMPRII was affected with the treatment of dexamethasone and FGF-2. Previous reports have shown that BMPRIA and BMPRII were induced by BMP-2 and it was hypothesized that the induction of BMPRIA and BMPRII may be sufficient for the induction of bone formation (14,18). The current study has demonstrated that the combination of 100 nM dexamethasone and 20 ng/ml FGF-2 produced the highest expression of BMPRIA and BMPRII, leading to the highest value of pSmad1/5/8 expression.

The results, in terms of the effect of the combination of dexamethasone and FGF-2 on osteoblastic differentiation may be controversial, due to the different systems, maturation stages of the cells studied, heterogenicity of the osteoblast population, culture conditions and species differences (2,19).

Within the limits of this study, dexamethasone significantly enhanced osteoblast differentiation, however, the combined delivery of dexamethasone and FGF-2 did not produce synergistic effects on osteoblast differentiation under the current experimental conditions. Additional studies are required to evaluate divergent conditions to select the optimal dosage and selective timing for the delivery of the agents.

Acknowledgements

This study was supported by Seoul St. Mary’s Clinical Medicine Research Program 2013 through the Catholic University of Korea.

References